Visby Medical’s Respiratory Health Test Receives Emergency Use Authorization from the US FDA
Shots:
- This test has been approved only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B
- This project has received support from many federal funds under contract number 75A50121C00019 that includes the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority
- The Visby Medical Respiratory Health Test is a palm-sized POC, accurate and rapid PCR device that detects and identify the difference between upper respiratory infections caused by Influenza A & B, and SARS-CoV-2 within 30mins
Ref: PR Newswire | Image: Visby Medical
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
